It has been a great start to the week for shareholders of cognitive science company CogState Limited (ASX: CGS). Its shares jumped a massive 22% this morning following the release of a positive first quarter update to the market.

CogState provides testing software to some of the world’s largest pharmaceutical companies that assists them in achieving more accurate results from their drug trials. Demand for its services has been growing strongly recently, not least in the most recent quarter.

For the quarter ended September 30 2016 the company reported an 82% jump in revenue over the prior corresponding period to $11.1 million.

Perhaps even more impressive though was the news that the company has a record pipeline of contracted revenue totalling $55.5 million. An estimated $28.7 million of this pipeline is expected to be recognised in the 2017 financial year.

Driving the strong performance were a series of new clinical trial contract signings. New contracts worth US$17.3 million were signed in the quarter, making it the largest quarter of contract signings in its history.

This ultimately meant the company was profitable in the first quarter and the future pipeline has given management the confidence to believe it will remain profitable for the first half of its financial year.

Whilst I really like CogState and believe it does have a bright future ahead of it, I wouldn’t necessarily rush into an investment just yet. Instead I would suggest investors wait until the company provides its full year guidance after its half year results.

Its shares are trading on high multiples and in my opinion the company will need to justify this in its guidance. Failure to do so could see its share price take a tumble, especially after its 267% rise in the last 12 months.

For now I would suggest investors add CogState to their watch lists and look at investing in other tech shares such as Altium Limited (ASX: ALU) and Aconex Ltd (ASX: ACX).

How 1 Man Turned $10K Into Over $8 Million

Discover how one man turned a modest $10,600 investment into an $8,016,867 fortune. Learn more about this man and how you can start down the path toward financial independence. Simply click here to learn more.

HOT OFF THE PRESSES: Motley Fool’s #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our https://www.fool.com.au/financial-services-guide">Financial Services Guide (FSG) for more information.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.